Bacterial Toxin Fusion Proteins Elicit Mucosal Immunity against a Foot-and-Mouth Disease Virus Antigen When Administered Intranasally to Guinea Pigs.

Actions of cholera toxin and the prevention and treatment of cholera. Nature (1981) 4.78

Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature (1991) 4.11

Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine (1988) 3.00

Comparison of heat-labile enterotoxins from porcine and human strains of Escherichia coli. Infect Immun (1982) 2.62

The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem (1992) 2.40

Structure and function of ARF proteins: activators of cholera toxin and critical components of intracellular vesicular transport processes. J Biol Chem (1995) 2.18

Origin of the enzymatically active A1 fragment of cholera toxin. J Infect Dis (1979) 1.95

Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today (1999) 1.74

Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine (2002) 1.13

Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology (2010) 1.10

Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of CD4(+) T cells. Infect Immun (2001) 1.02

Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells. Infect Immun (2005) 1.02

Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. Infect Immun (2010) 1.00

Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin. Infect Immun (1998) 0.97

Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice. Vaccine (2007) 0.97

Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis. Infect Immun (2004) 0.96

Immune response versus mucosal tolerance to mucosally administered antigens. Vaccine (2005) 0.91

1st class ticket to class I: protein toxins as pathfinders for antigen presentation. Traffic (2002) 0.89

LRP 1 B functions as a receptor for Pseudomonas exotoxin. Biochim Biophys Acta (2005) 0.89

A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge. Vaccine (2003) 0.89

Characterization of V3 loop-Pseudomonas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1. J Biol Chem (1998) 0.85

Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses. Vaccine (1999) 0.85

Peroral immunization with Helicobacter pylori adhesin protein genetically linked to cholera toxin A2B subunits. Clin Sci (Lond) (2001) 0.85

Bacterial toxins as tools for mucosal vaccination. Drug Discov Today (2002) 0.85

An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infect Immun (2003) 0.83

Cholera toxin and related enterotoxins: a cell biological and immunological perspective. J Nat Toxins (2000) 0.83

Non-toxic Pseudomonas aeruginosa exotoxin A expressing the FMDV VP1 G-H loop for mucosal vaccination of swine against foot and mouth disease virus. Vaccine (2007) 0.81

ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity. Ann N Y Acad Sci (2004) 0.80

Gene fusion of cholera toxin B subunit and HBV PreS2 epitope and the antigenicity of fusion protein. Vaccine (1995) 0.79

A novel mucosal vaccine against foot-and-mouth disease virus induces protection in mice and swine. Biotechnol Lett (2005) 0.78

Enhanced phosphorus nutrition in monocots and dicots over-expressing a phosphorus-responsive type I H+-pyrophosphatase. Plant Biotechnol J (2007) 1.26

An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine. Vaccine (2013) 0.93

Outer membrane protein A (OmpA) of Cronobacter sakazakii binds fibronectin and contributes to invasion of human brain microvascular endothelial cells. Foodborne Pathog Dis (2009) 0.90

Quantifying specific antibody concentrations by enzyme-linked immunosorbent assay using slope correction. Clin Vaccine Immunol (2006) 0.90

Chemokine and cytokine gene expression profiles in chickens inoculated with Mycoplasma gallisepticum strains Rlow or GT5. Vaccine (2007) 0.89

Labeling and intracellular tracking of functionally active plasmid DNA with semiconductor quantum dots. Mol Ther (2006) 0.89

Broncho-alveolar macrophages express chemokines associated with leukocyte migration in a mouse model of asthma. Cell Immunol (2013) 0.86

Correlates of immune protection in chickens vaccinated with Mycoplasma gallisepticum strain GT5 following challenge with pathogenic M. gallisepticum strain R(low). Infect Immun (2005) 0.85

A microarray biosensor for multiplexed detection of microbes using grating-coupled surface plasmon resonance imaging. Environ Sci Technol (2011) 0.85

Use of inactivated Escherichia coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine. Clin Vaccine Immunol (2011) 0.84

Semi-automated curation of metabolic models via flux balance analysis: a case study with Mycoplasma gallisepticum. PLoS Comput Biol (2013) 0.84

Long-Term Exposure to House Dust Mite Leads to the Suppression of Allergic Airway Disease Despite Persistent Lung Inflammation. Int Arch Allergy Immunol (2015) 0.82

Non-toxic Pseudomonas aeruginosa exotoxin A expressing the FMDV VP1 G-H loop for mucosal vaccination of swine against foot and mouth disease virus. Vaccine (2007) 0.81

Tbx1 modulates endodermal and mesodermal differentiation from mouse induced pluripotent stem cells. Stem Cells Dev (2014) 0.79

Diagnosis of Porcine teschovirus encephalomyelitis in the Republic of Haiti. J Vet Diagn Invest (2012) 0.78

LC-MS/MS Identification of a Bromelain Peptide Biomarker from Ananas comosus Merr. Evid Based Complement Alternat Med (2012) 0.77

Dual fluorescent labeling method to visualize plasmid DNA degradation. Bioconjug Chem (2009) 0.77

c-Met signalling is required for efficient postnatal thymic regeneration and repair. Immunology (2015) 0.76

Effects of sialidase knockout and complementation on virulence of Mycoplasma gallisepticum. Vet Microbiol (2011) 0.76

Modulating gene expression using DNA vaccines with different 3'-UTRs influences antibody titer, seroconversion and cytokine profiles. Vaccine (2003) 0.76

Cloning and characterization of a hybridoma secreting a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-specific monoclonal antibody and recombinant F(ab). Toxins (Basel) (2013) 0.75

Xenoepitope substitution avoids deceptive imprinting and broadens the immune response to foot-and-mouth disease virus. Clin Vaccine Immunol (2012) 0.75